EFFECTIVE 01 Mar, four new cancer treatments recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) will be funded by the Federal Government under their policy of supporting all PBAC-recommended products.
Federal Minister for Health Greg Hunt announced the commitment.
At an estimated cost of $200m, lymphocytic leukaemia treatment Venclexta (venetoclax), Opdivo (nivolumab) and Yervoy (ipilimumab) for previously untreated stage IV clear cell variant renal cell carcinoma, Keytruda (pembrolizumab) for locally advanced or metastatic urothelial cancer and advanced hepatocellular carcinoma treatment Lenvima (lenvatinib) are to be funded.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Feb 19
